1. Goranchyk V.V., Shustov E.B. Biochemical indexes in development of extreme hyperthermia // Fiziologiya cheloveka. 1997. 23. (4). 98–105. (in Russian)
2. Patent 2165105 RF. Way of experimental modeling general hyperthermia for small laboratory animals / Efremov A.V., Pakhomova Y.V., Pakhomov E.A. et al.; published 10.04.2001. (in Russian)
3. Zubareva E.V., Seferova R.I. Changing in lipid composition of rat tissues under hyperthermia of different degrees // Voprosy meditsinskoy khimii. 1992. (3). 50–53. (in Russian)
4. Kamyishnikov V.S. Guide to the clinic-biochemical laboratory diagnostics. Minsk: Belarus, 2002. 2. 464 p. (in Russian)
5. Boeckh-Haebisch E.M., Fernandes L.C., Ponzoni M. et al. Cationic and water content in blood, skeletal muscle and liver of food restricted and Walker 256 tumor-bearing rats // Cancer Res. Ther. Control. 1998. 5. 213–219.
6. Cintra-Gomes M.C., Cury L., Parreira M.R. et al. Effects of Walker 256 carcinoma on metabolic alterations during the evolution of pregnancy // Braz. J. Med. Biol. Res. 1990. 23. (9). 909–913.
7. Fernandes L.C., Machado U.F., Nogueira C.R. et al. Insulin secretion in Walker 256 tumor cachexia // Am J Physiol. 1990. 258(6). E1033–E1036.
8. Keller H., Eggli P. Protrusive activity, cytoplasmic compartmentalization, and restriction rings in locomoting blebbing Walker carcinosarcoma cells are related to detachment of cortical actin from the plasma membrane // Cell Motil. Cytoskeleton. 1998. 41. (2). 181–193.
9. Khegai I.I., Popova N.A., Zakharova L.A., Ivanova L.N. Walker 256 tumor growth in rats with hereditary defect of vasopressin synthesis // Bull. Exp. Biol. Med. 2006. 142. (3). 344–346.
10. Lushnikova E.L., Ovsyanko E.V., Nepomnyashchikh L.M. et al. Proliferation of Walker 256 carcinosarcoma cells: effect of whole-body hyperthermia and antitumor agents // Bull. Exp. Biol. Med. 2011. 152. (1). 146–152.
11. Pires L.A., Hegg R., Valduga C.J., Graciani S.R., Rodrigues D.G., Maranhao R.C. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of brest cancer: pharmacokinetics, tumor uptake and a pilot clinical study 2009 // Cancer Chemother. Pharmacol. 2009. 63. (2). 281–287.
12. Rebeca R., Bracht L., Noleto G.R. et al. Production of cachexia mediators by Walker 256 cells from ascitic tumors // Cell Biochem. Funct. 2008. 26. (6). 731–738.
13. Seelaender M.C., Ambrico C., Rodrigues M.C.P.S. Hormonal alterations in Walker 256 tumor-bearing rats: possible role of calcium for the maitenance of cachexia // Cancer Res. Ther. Control. 1996. 5. (1). 29–33.
14. Spirina L.V., Bochkareva N.V., Kondakova I.V. et al. Regulation of insulin-like growth factors and NF-kappaB by proteasome system in endometrial cancer // Mol. Biol. (Mosk.). 2012. 46. (3). 452–460.
15. Tamburrini A.L., Woolcott C.G., Boyd N.F. et al. Associations between mammographic density and serum and dietary cholesterol // Breast Cancer Res. Treat. 2011. 125. (1). 181–189.
16. Vrionis F.D., Wu J.K., Qi P., Cano W.G., Cherington V. Tumor cells expressing the herpes simplex virus-thymidine kinase gene in the treatment of Walker 256 meningeal neoplasia in rats // J. Neurosurg. 1996. 84(2). 250–257.
17. Yetukuri L., Huopaniemi I., Koivuniemi A. et al. High density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy // PloS One. 2011. 6. (8). e23589.
18. Zecchin K.G., Seidinger A.L., Chiaratti M.R. et al. High Bcl-2/Bax ratio in Walker tumor cells protects mitochondria but does not prevent H2O2-induced apoptosis via calcineurin pathways // J. Bioenerg. Biomembr. 2007. 39. (2). 186–194.
19. Zylicz Z., Schwantje O., Wagener D.J., Folgering H.T. Metabolic response to enteral food in different phases of cancer cachexia in rats // Oncology. 1990. 47. (1). 87–91.